{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:57:31Z","timestamp":1791280651065,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":648,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"CA09515"},{"name":"CA18029"},{"name":"CA15704"},{"name":"CA162059"},{"name":"CA76930"},{"name":"National Institutes of Health"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.bbmt.2013.04.005","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T11:48:07Z","timestamp":1365594487000},"page":"1033-1039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes"],"prefix":"10.1016","volume":"19","author":[{"given":"Andrew R.","family":"Rezvani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine S.","family":"McCune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry E.","family":"Storer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Batchelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George B.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2013.04.005_bib1","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":"Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation","volume":"89","author":"Slattery","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.005_bib2","first-page":"31","article-title":"Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib3","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2004-05-1947","article-title":"Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age","volume":"105","author":"Alyea","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.005_bib4","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1182\/blood-2012-04-423046","article-title":"Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS","volume":"120","author":"Deeg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.005_bib5","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/hep.510240414","article-title":"Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation","volume":"24","author":"DeLeve","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.bbmt.2013.04.005_bib6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000028359","article-title":"Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes","volume":"60","author":"DeLeve","year":"2000","journal-title":"Pharmacology"},{"key":"10.1016\/j.bbmt.2013.04.005_bib7","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.005_bib8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00280-011-1736-3","article-title":"A\u00a0pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients","volume":"69","author":"McCune","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2013.04.005_bib9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/bmt.2010.190","article-title":"Targeted i.v. BU and fludarabine (t-i.v. BU\/Flu) provides effective control of AML in adults with reduced toxicity","volume":"46","author":"Pidala","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/clpt.2009.27","article-title":"Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy","volume":"85","author":"McCune","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bbmt.2013.04.005_bib11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2307\/3578033","article-title":"Radiation hepatology of the rat: microvascular fibrosis and enhancement of liver dysfunction by diet and drugs","volume":"129","author":"Geraci","year":"1992","journal-title":"Radiat Res"},{"key":"10.1016\/j.bbmt.2013.04.005_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.510310224","article-title":"Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat","volume":"31","author":"Wang","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.bbmt.2013.04.005_bib13","first-page":"135","article-title":"Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children","volume":"10","author":"Meresse","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/bmt.2008.404","article-title":"The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans","volume":"43","author":"Kerbauy","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/bmt.2010.137","article-title":"Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT","volume":"46","author":"Cantoni","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib16","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.bbmt.2012.04.011","article-title":"Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation","volume":"18","author":"Wong","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbmt.2011.06.013","article-title":"Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hemtopoietic cell transplant recipients","volume":"18","author":"Yeh","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bbmt.2007.03.012","article-title":"Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality","volume":"13","author":"McCune","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00007691-199810000-00017","article-title":"Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation","volume":"20","author":"Slattery","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bbmt.2013.04.005_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.bbmt.2013.04.005_bib21","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2007-03-078592","article-title":"Relapse risk among patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.005_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.clpt.2004.05.006","article-title":"Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard","volume":"76","author":"Qiu","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bbmt.2013.04.005_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.bmt.1704697","article-title":"Accidental busulfan overdose during conditioning for stem cell transplantation","volume":"35","author":"Jenke","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib24","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.3109\/10428194.2010.520773","article-title":"Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome\/veno-occlusive disease","volume":"51","author":"O'Donnell","year":"2010","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.bbmt.2013.04.005_bib25","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.bbmt.2011.12.584","article-title":"Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation","volume":"18","author":"Perkins","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib26","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.bbmt.2012.02.006","article-title":"Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation","volume":"18","author":"Zhang","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1078155210392616","article-title":"Once-daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant","volume":"18","author":"LeMaistre","year":"2012","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.bbmt.2013.04.005_bib28","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.bbmt.2004.05.010","article-title":"Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies","volume":"10","author":"Williams","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib29","first-page":"18","article-title":"Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens","volume":"20","author":"Grochow","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2013.04.005_bib30","first-page":"225","article-title":"Association of busulfan area under the curve with veno-occlusive disease following BMT","volume":"17","author":"Dix","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.exphem.2004.12.003","article-title":"Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice","volume":"33","author":"Nilsson","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2013.04.005_bib32","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/sj.bmt.1705996","article-title":"The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model","volume":"41","author":"Sadeghi","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/bbmt.2002.v8.pm12374454","volume":"8","author":"Kashyap","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.005_bib34","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2006-06-025627","article-title":"Results of a HOVON\/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?","volume":"109","author":"Cornelissen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.005_bib35","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N\u00a0Engl J Med"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911300150X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911300150X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:44:39Z","timestamp":1761057879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387911300150X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S108387911300150X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.04.005","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}